Merck is now rapidly producing drugs that counteract over-immune response to Covid patients – German scientists: Oxford / AstraZeneca vaccine less than 8% effective in over-65s
Pharmaceutical giant Merck has stopped the development of two corona vaccines. After all, thorough research has shown what scientists such as professor (em.) Pierre Capel have been saying for months, namely that the human immune system offers much better protection than a vaccine.
Merck’s vaccines V590 and V591 are said to be ‘well tolerated’ by subjects, but trigger an ‘inferior’ immune response compared to the human immune system. Merck will now focus on common anti-coronary drugs, which are tentatively designated MK-7110 and MK-4482. These drugs are supposed to protect corona patients against an overactive immune response to the virus (cytokine storm).
”Interim results from a phase 3 study show a greater than 50% reduction in the risk of death or respiratory failure in patients admitted to hospital with moderate or severe Covid-19.” The company will receive $ 336 million from the US government to develop and manufacture these resources as quickly as possible.
Michael Nally, Merck’s chief of marketing, recently stated that some 20 million courses of the MK-4482 drug, an oral antiviral drug to be taken twice a day for five days, will be produced.
Oxford / AstraZeneca vaccine less than 8% effective in people over 65
According to German scientists, the Oxford / AstraZeneca ‘chimpanzee’ vaccine, which was purchased by Minister De Jonge last year before it was even developed and tested at all, is less than 8% effective in people over 65. The German media wrote that this has been confirmed by several government sources.
This should not come as a surprise either. Scientists like Pierre Capel have warned from the outset that it is pretty pointless to give older people a vaccine, because their immune systems are no longer functioning properly anyway. A vaccine can even cause damage and be dangerous.
Source: Summitnews / Xander
Jerry Sträng 